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This spring Professor Zanvil A. Cohn and members of his
Rockefeller University laboratory flew to Brazil. They went
to follow up clues, uncovered during an earlier trip, as to why
certain cells of the immune system that should kill leprosy
bacteria fail to do so. If the clues are correct, they may help
strengthen some current ideas about the incompletely under-
stOod mechanisms of the body's immune defense. They have
already provided a useful new tool for diagnosing leprosy.
Among Dr. Cohn's co-workers are scientists who, in addi-
tion to leprosy, have been studying Legionnaires' disease,
Chagas' disease, leishmaniasis, and cancer. Central to their
research is the macrophage, a white cell named for its large
size and its most obvious activity-eating. The macrophage
belongs to the cell-mediated immune system, a network that
normally prevents hostile forces such as microbes and tumors
from gaining a foothold in body tissue.
Immunologists are learning that sometimes macrophages
ingest these pathogens but do not kill them as they should;
instead, they provide the invaders with a sheltering nest in
which to thrive and multiply. This phenomenon, which was
observed in Legionnaires' disease by Marcus Horwitz in Dr.
Cohn's lab, also occurs in tuberculosis and leprosy, as well as
with protOzoan parasites. Dr. Horwitz found that macro-




Legionnaires' disease, could multiply as much as 10,OOO-fold,
causing the macrophages to burst within only three days.
Samuel C. Silverstein, a member of the laboratory for many
years, likened macrophages in this state to "Trojan horses."
In cell-mediated immunity, the white cells that are sup-
posed to recognize and apprehend pathogens are called T
lymphocytes. (This is analogous to the humoral immune sys-
tem that operates in body fluids and tissues where B lympho-
cytes secrete antibody molecules. These lock into antigen
"keyholes." Antigens are the molecules on the surface mem-
brane of invading organisms against which antibodies are pro-
duced.) Some T cells are killer cells, while some summon
macrophages. Some T cells help macrophages, and some,
immunologists now realize, actually suppress immune
responses.
"What makes leprosy a particularly interesting model for
study," says Dr. Cohn, "is that it appears in a whole spectrum
of forms. In the lepromatous form-the most virulent-bac-
teria multiply uninhibitedly, with the unfortunate results we
normally associate with the disease. Then there are gradations
down to the mildest or tuberculoid form, in which the
immune system does effectively limit bacterial spread.
"For some reason no one had ever really looked very hard
at the local skin lesions of leprosy patients. Diagnosis has
usually been based on analysis of cells in the blood stream. So
when we first went to Brazil, we decided that we would exam-
ine the cells in the skin. In the virulent lepromatous lesions
we found bacteria-filled macrophages together with a large
number of suppressor T cells. As we studied patients in the
intermediate stages of the disease and on to the tuberculoid
form, we found that the number of so-called helper cells
began to increase relative to the number of suppressor T
cells.
"We think that the suppressor cells produce a factor which,
in effect, turns off the macrophage. Or else, the macrophages
don't work because of the absence of helper cells. The ques-
tion is, Can you suppress the suppressors or help the helpers?
Some experiments we've been doing in the lab with cells of
other diseases indicate that either or both may be possible,
but we need to know a lot more about the bacteria and the
immune cells before we can manipulate them clinically. In
Brazil, where leprosy is widespread, new cases are admitted
to hospitals all the time, which makes it possible to get cells
for study before they are modified by treatment.
"What we can learn about these suppressor cells," Dr.
Cohn explains, "is also of great interest because there's a fair
amount of evidence in many animal models that suppressor
cells modify the ability of a host to fight off tumors, and that if
you can destroy the suppressor cells, you'll allow normal body
defenses to come back and destroy the tumor."
CHARTING THE TERRITORY
Zanvil Cohn has been stalking white cells for most of his pro-
fessional career. He grew up on Long Island, where he still
lives, and where he and his wife and family relax by deep-sea
fishing. He came to Rockefeller in 1958 after earning a medi-
cal degree summa cum laude at Harvard and serving a stint in
uniform as head of a unit at the Walter Reed Army Institute
for Research. While he was still in medical school, his interest
in research had been spurred by a series of technological
advances that were dramatically expanding the scope of cell
biology. His interest in Rockefeller stemmed from the fact
that many of the advances, in electron microscopy, cell frac-
tionation, and immunology, were happening there.
Today, with scientists manipulating molecules and recom-
bining genes, it's easy to lose sight of the fact that, until
recently, the inner world of living cells was essentially
uncharted territOry. Less than twenty years ago, James
Hirsch, formerly co-leader with Dr. Cohn of the laboratory of
cellular physiology and immunology, was quoted as saying:
"For the first time now, in the past decade, techniques have
been developed that allow us ro look inside the cell with some
degree of precision and reliability. A whole new field has
opened up and we have only scratched the surface."
Dr. Cohn and Dr. Hirsch both began their Rockefeller
careers under the late Rene Dubos, whose microbiological
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studies were critical to the development of antibiotics. In
those days, the stunning success of the "wonder drugs" in
fighting bacterial infection was accompanied by a lack of any
real knowledge of how they worked. Dr. Cohn's first project
in Dr. Dubos' lab, conducted with the late Steven Morse, was
to ascenain that polymorph leukocytes, white-cell cousins of
macrophages (although that was not known then), are the
cells that kill the bacteria of "staph" infections.
Polymorphs are front-line defenders in the immune sys-
tem. Like macrophages, they are phagocytes, cells that ingest
their prey. A couple of years after coming to Rockefeller, Dr.
Cohn collaborated with Dr. Hirsch to find out, among other
things, whether the tiny granules that could be seen within
polymorphs were, as was suspected, the instruments of
microbe killing. Before they could learn that, however, they
had to get the granules out of the cells intact, something no
one had been able to do. After months of effon, Dr. Cohn
found the solution. With the granules free, their COntent of
tOxic chemicals and digestive enzymes could be identified,
establishing the granules as a type of lysosome or cellular
"stOmach." After microbes are internalized, the cell delivers
its granule contents into the phagocytic vacuole-the killing
ground.
Macrophages, which Dr. Cohn began exploring about
twenty years ago, are bigger and more complicated than poly-
morphs. They live longer and make more chemical products,
some fifty of which have been identified to date, many in the
Cohn laboratOry. They begin life in the bone marrow, deriv-
ing from the same precursor cells as polymorphs. As young
cells, they are monocytes, named for their single nuclear
shape, in contrast to the many different nuclear shapes of
polymorphs. Monocytes circulate in the blood for a time
before maturing into macrophages of various types, which
take up residence in different body tissues. The phagocytic
family tree was plotted a decade ago by Dr. Cohn with Dr.
Ralph van Funh, ~ow working in The Netherlands.
THE "THIRTY-MINUTE FRENZY":
RECEPTORS AND ."ZIPPERS"
Macrophages are the most omnivorous of the phagocytes. In
addition to eating pathogens, they eliminate aged body cells.
In the human system this includes some 300 billion defunct
red blood cells each day. Macrophages achieve this awesome
intake by the process of endocytOsis. When a ponion of the
cell's outer membrane comes in contact with a panicle, the
membrane surrounds the panicle to form a sac, called a
vacuole, that tucks intO the cell. Small vacuoles are fluid filled
and are pan of cell drinking or pinocytOsis, the ingesting of
panicles in solution. Large vacuoles enclose solid panicles as
big as whole cells. The vacuole then separates from the cell
surface and fuses with the lysosome to initiate the process of
intracellular digestion.
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Endocytosis and membrane recycling
"During our studies of endocytosis," Dr. Cohn says, "we
wanted to find out how much membrane flows into the cell, at
what rate, and what happens to it. Ralph Steinman, who
joined the lab in 1970, devised elegant methods for following
the uptake of labeled enzymes by pinocytosis. As a result, we
learned that the cell takes in its entire surface area, as small
vesicles, every thirty-three minutes. Then we wondered
whether the membrane is destroyed in the lysosome and new
membrane synthesized, or whether it is recycled. We worked
out a preny neat trick for labeling only the inner membrane
of the lysosome, based upon a procedure of a former student,
Ann Hubbard, who's now on the faculty ofJohns Hopkins. If
the membrane was recycling, we knew the isotope would
show up sooner or later on the surface of the cell. And within
a period of five minutes thar's exacrly what happened."
The efficiency and speed of endocytosis helps to explain
how the macrophage can envelop, in its "thirty-minute phago-
Zanvil Cohn and
, Ralph Steinman
cytic frenzy" (as one researcher phrased it), a quantity of mat-
ter equal to half its own mass. But chaos would ensue if the
macrophage had no means for discriminating what should or
should not be devoured. Jay Unkeless, another member of
the group, has been isolating from the cell membrane the
receptor molecules, the "taste buds," through which a macro-
phage perceives that a particle is fit for consumption.
The receptor binds to microbes and cells that are coated
with specific antibodies, which is the way the macrophage is
able to recognize "foreignness." Receptors have been isolated
from both mouse and human cells through the use of mono-
clonal antibodies, exquisitely precise reagents which zero in
on specific molecules. It is hoped that through the use of
recombinant ON A technology enough receptor will be pro-
duced ro allow the determination of its structure.
Once the prey is attached to the macrophage's surface-
membrane receptors, it is engulfed by a "zipper mechanism,"
a process discovered by Samuel Silverstein. Antigens on the
prey continually combine with phagocyte receptors, resulting
in a flow of membrane around the particle. When the prey is
completely surrounded by host-cell membrane, fusion occurs
and the phagocytic vacuole is formed .
NATURE'S ADJUVANTS
While examining the spleen macrophages of mice, Dr. Stein-
man and Dr. Cohn discovered an entirely new class of
immune cells. "These represented a tiny population and
because of their branched appear~nce we named them den-
dritic cells," Dr. Cohn explains. "After a number of years of
work, Ralph and his group have been able to isolate and char-
acterize these cells in both animals and man. Of great interest
is their unique ability to stimulate the cell division of lympho-
cytes. In other words they are accessory cells- 'adjuvants,'
Ralph calls them-needed to initiate an immune response.
Since they are the most potent stimulators of transplantation
















TO PROTECT OR DESTROY?
A major immunological finding, which has come primarily
from work in Dr. Cohn's laboratory, is that macrophages are
not just eaters. In addition to the chemicals they make to kill
and degrade the cells they ingest, they also secrete many mol-
ecules into their surrounding environment, affecting the
activity of other cells.
''This is an important part of the inflammatory process,
which may lead either to wound healing and tissue repair or
to clestruction of tissues," says Dr. Cohn. "Among the secreted
chemicals are those that stimulate the formation of blood cells
and blood vessels; pyrogens, the fever-producing substances;
and enzymes involved in lipoprotein metabolism. A delicate
balance exists in the amount and nature of the secretory prod-
ucts. When present in excessive amounts disease states such
as rheumatoid arthritis, glomerulonephritis, and even ath-
erosclerosis may be potentiated.
"We've also learned that macrophage membrane is one of
the richest sources in the body of arachidonic acid and its
metabolites. William Scott and Nicholas Pawlowski have
been studying arachidonic acid metabolites, the two main
classes of which are the leukotrienes and the prostaglandins.
Both have profound effects on the inflammatory process.
Some of these macrophage products may directly influence
the smooth muscles of lung and blood vessels. Some stimu-
late the production of prostaglandins by other cells leading to
a 'metabolite cascade.' One of the leukotrienes they've iso-
lated acts strongly to attract circulating polymorphs and mo-
nocytes to the lungs in response to infections and tumors.
Obviously, knowing how to control the production of these
potent mediators of inflammation will have clinical
applications. .
"Of the macrophage's cell-killing chemicals," he continues,
"the group called toxic oxygen intermediates attack a whole
variety of targets both inside and outside the cell. Carl
Nathan, who was trained as an oncologist, has found that
macrophages secrete large, amounts of hydrogen peroxide,
which kills tumors. But tumors, like microbes, vary in their
susceptibility. Some, as we've learned, contain substances that
block the effect of the hydrogen peroxide. In experiments in
the test tube and with mice, we've been able to turn off the
blocker synthesis in the tumor cells. We've also tried increas-
ing the macrophage's hydrogen peroxide production. This is
an area where interferon may one day be clinically useful,
specifically gamma interferon, which is a strong macrophage
stimulator." (Interferons are small proteins produced by
virus-infected and immune cells as a defense mechanism. Sci-
entists are now able to synthesize interferons using recombin-
ant DNA technology.)
"The problem when dealing with human subjects is one of
--
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Members 0/ the Cohn lab on
the first trip to Brazil. From
left: Bradley Arrick, Gilla
Kaplan, Wesley Van Voorhis,
and Marcus Horwitz.
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designing means to deliver chemicals safely and to specific
target tissues within the body. This is one of the areas that
Carl and others in the lab are working on."
"IT JUST SORT OF HAPPENED... "
For Nadia Nogueira, the trip to Brazil was a trip home. Like a
number of others in Dr. Cohn's group, she came to the Uni-
versity as a Ph.D. student. Also like many of the grOup, she is
a physician. She came because of her deepening frustration
with trying to be a doctor in a part of the world where most of
the diseases people suffer from cannot be cured, prevented,
or, often, even treated. In Latin America, Chagas' disease
afflicts 50 million people and can cause fatal heart damage. It
is a parasitic disease, as is leishmaniasis, which is also rampant
in latin America and, in slightly different forms, in Africa,
Asia, and the Middle East.
Dr. Nogueira can pinpoint the moment she was finally
"pushed intO research," as she says. "In the hospital in Rio
where I was doing my internship, there were hundreds of
patients with leishmaniasis. In its invasive form, it's a horrible,
deforming disease, and there was nothing we could do for
these patients. There had been a drug that worked reasonably
well to contain the progression of the' disease, but it had been
taken off the market. It wasn't profitable. later, it was again
made available through governmental production, but by
then I had already determined that we must have vaccines."
When she first came to the United States, she found that
tropical medicine interested few American scientists. "When
I tOld people that I wanted to work on Chagas' disease, they
would say to me 'work on cancer.' Well, most people in my
country rarely live long enough to die of cancer. There were
suggestions in the clinical literature that macrophages were
involved in Chagas' disease, so I went to Zan and asked if I
could do my thesis in his lab. He asked me how I planned to
go about it and how I would handle the problem of the high
infectivity of the parasites. I tOld him, and he said, 'Okay, why
don't you try it.' Then he gave me the ideal combination of
tOtal freedom to work and tOtal availability when I needed
help. His insight is unfailing. How did the leprosy project
start) It just sort of happened naturally, I guess, after about a
million convers..ations about macrophages and how they act."
For ten years, Dr. Nogueira has been exploring the interac-
tion of macrophage and parasites, first in Chagas' disease and
more recently in leishmaniasis. Lately, with the help of Dr.
Unkeless, an expert in monoclonal antibody technology, and
cell biologist Paul Lizardi, a member of another Rockefeller
laboratory, she has identified the major surface antigen of
these parasites and started cloning the genes coding for them.
Vaccines may not be very far away. Dr. Cohn's support of
young scientists is reflected in the large number of them in his
laboratory and in his stewardship, for many years, of the Uni-
versity's joint MD.-Ph.D. program with Cornell University
Medical College, which also reflects his commitment to clini-
cal medicine.
One of the students currently in his group and in the MD,-
Ph.D. program is Wesley Van Voorhis, who made the major
contribution to the findings about leprosy gathered on the
first trip to Brazil. Mr. Van Voorhis didn't go on the second
trip. He stayed home to finish his thesis, on human dendritic
cells.
